Iaso Biotherapeutics（驯鹿生物）

IASO BioTherapeutics, also known as 驯鹿生物, is a leading Chinese biotechnology company specializing in the research, development, and commercialization of innovative cell therapies and immunotherapies for cancer and autoimmune diseases. The company generates revenue primarily through the development and licensing of CAR-T cell therapies, including its flagship product Equecabtagene Autoleucel, which has received regulatory approval in China for treating relapsed or refractory multiple myeloma. Founded in 2017 and headquartered in Nanjing, IASO BioTherapeutics has built a robust pipeline of clinical-stage assets and strategic partnerships with global pharmaceutical firms. The company is recognized for its integrated capabilities spanning R&D, manufacturing, and commercialization, and has attracted significant investment from prominent venture capital firms. Candidates should be aware of IASO’s rapid growth, strong focus on innovation, and its ambition to expand internationally within the competitive cell therapy landscape.

Recent Posts by Iaso Biotherapeutics（驯鹿生物）

1-1 of 1